Gamma delta T-cells in leukemia and myelodysplastic syndromes after transplant
Tests gamma delta T-cells in people with leukemia after transplant.
Key facts
- Who runs it
- University of Kansas Medical Center
- Where
- Columbus and Westwood, United StatesSee the 2 sites
- Trial code
- Registry title
- Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 38 people, planned
- Started
- 31 Jan 2020
- Expected to end
- Jan 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- EAGD T-cell infusion (Phase I)
- EAGD T-cell infusion (Expansion)
- Record updated
- 25 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 19-65 with certain blood cancers (AML, CML, ALL) or myelodysplastic syndrome who need a stem cell transplant from a partly matched donor. They receive donor gamma delta T-cells after the transplant.
- Age
- 19-65 years.
- Sex
- All sexes can join.
- Disease stage
- AML in complete remission with intermediate/high-risk features, or relapsed. CML in any chronic phase. MDS with intermediate/high-risk features or refractory disease (bone marrow blast count <10%). ALL in complete remission with high-risk features, or relapsed.
- Earlier treatment
- A donor-specific antibody test must be negative within 28 days of starting the conditioning regimen. Before the T-cell infusion, neutrophil engraftment is needed and there must be no acute graft versus host disease (any grade).
- Biomarker or test result
- Heart ejection fraction (LVEF) 50% or above. FVC, FEV1 and DLCO 50% or above of expected. Serum creatinine <2 mg/dl (177 µmol/L) and creatinine clearance 70 mL/min/1.73 m2 or more. Karnofsky or Lansky score ≥80. HCT-CI <3.
Main reasons for not taking part
- Active cancer involvement of the brain or spinal cord (CNS)
- HIV1 or HIV2 positive
- Pregnant or breastfeeding women
- Known allergy to DMSO
- Morbid obesity with body mass index >35
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- The following criteria are used to enroll patients in the study before transplant
- Patients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (NCCN) or other standard guidelines as follows:; Acute myeloid leukemia [AML] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease; Chronic myeloid leukemia [CML] in any chronic phase; Myelodysplastic syndrome [MDS] with intermediate/high risk features or refractory disease (with bone marrow blast count <10%); Acute lymphoblastic leukemia [ALL] in morphologic complete remission with high-risk features or relapsed disease
- Negative test for donor-specific antibody within 28 days of starting conditioning regimen
- Age Criteria: 19-65 years
- Organ Function Criteria: The following organ function testing should be done within 35 days before study registration; Cardiac: Normal left ventricular ejection fraction (LVEF) (50% or above) as measured by MUGA or Echocardiogram; Pulmonary: FVC, FEV1 and DLCO (corrected) should be 50% or above of expected; Renal: serum creatinine level to be <2 mg/dl AND estimated (Cockcroft-Gault formula) or measured (takes priority if done) creatinine clearance (CrCl) must be equal or greater than 70 mL/min/1.73 m2; Hepatic: serum bilirubin 1.5 upper limit of normal (ULN), Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN, and alkaline phosphatase 2.5 ULN
- Performance status: Karnofsky performance score (KPS) or Lansky score: ≥80
- Hematopoietic cell transplant comorbidity index (HCT-CI) <3. Exception may be made on individual cases after discussion with the primary investigator
- Consent: All patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines; The following criteria are required within 48 hours prior to infusion of the EAGD T cell product
- Absence of uncontrolled infection with sepsis syndrome (e.g persistent positive blood culture)
- NO hemodynamic instability (due to sepsis or organ dysfunction) or circulatory volume overload
- NO clinically significant organ toxicity that are defined as follows:; Heart failure with subnormal LVEF or clinical fluid overload; Elevated serum creatinine or subnormal creatinine clearance (either estimated or measured); Elevated total bilirubin ≥1.5 upper normal level (unless indirect hyperbilirubinemia attributed to non-hepatic pathology), or elevated liver enzymes (ALT, AST, ALP) >5 x ULN; Hypoxemia requiring oxygen therapy
- NO acute graft versus host disease (any grade)
- Neutrophil engraftment
Who cannot take part
- Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician)
- Patients with known allergy to DMSO
- Non-compliant patients
- No appropriate caregivers identified
- Active central nervous system (CNS) neoplastic involvement
- Morbid obesity with body mass index >35 (borderline cases may be considered on case-by-case basis after discussion with the primary investigator)
- HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive
- Pregnant or breastfeeding women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Ohio State University Medical CenterColumbus, United StatesContact: Clinical Trial Nurse NavigatorTaking people
- University of Kansas Cancer CenterWestwood, United StatesContact: Clinical Trials Nurse NavigatorTaking people
About the trial
What the trial wants to find out
Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
The 2 groups in the trial
- EAGD T-cell infusion (Phase I)Treatment being tested
Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
- EAGD T-cell infusion (Expansion)Treatment being tested
Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- Plain-language title
- Gamma delta T-cells in leukemia and myelodysplastic syndromes after transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03533816, who can take part
- Record updated
- 25 March 2026